Primary Health Net
Visit our Public Information Site
Go to my LOC site
eros jobs online newsletter

Opchat Magazine Professional Matters Pages

Professional Matters Ophthalmology News, July to September 2017

For Optometry Section Click Here

Hutchinson becomes President at Royal Society of Medicine.
5 Reasons why you should be tempted to attend Ophthalmic Drugs 2017 Event.
Integumen signs Worldwide Patent Licence Agreement for remaining 50% of rights to Botox Booster IP
Heidelberg 9th Picture Competition in Vision Research & Ophthalmology ends September 30th
Eye health sector joined up to help patients remain independent.
Ophthalmic Drugs Conference: Advancing Your Ocular Drug Pipeline
FDA Approves iDesign Advanced WaveScan Studio System to Treat Hyperopia With and Without Astigmatism.
Bausch + Lomb Launches Fortifeye Capsular Tension Ring.
Review of artificial vision technologies showing that the Argus II bionic eye is fundable.

Hutchinson becomes President at Royal Society of Medicine.

September 2017

Bob HutchinsonAt last week’s GP with Primary Healthcare section AGM, Dr. Susan Horsewood Lee the outgoing President passed over that role to Bob Hutchinson for the following two academic years starting October this year.

Bob Hutchinson, the CEO of PHN Ltd and Editor of Opchat News and the public education site Mylocaloptician became only the second non-medic to be awarded the office in RSM history.

Speaking to an audience at the Annual Dinner he introduced himself and described his career as an optometrist both in community services and in hospital as well as a long career in primary care and optical politics.

This broad experience, he said, had provided him with an insight on the needs of primary care provision especially from an increasing elderly patient base in the UK.

Now more than ever primary care workers from different professional settings must come together, their combined strength being greater than their individual worth.

“In my two years in office I hope to facilitate shared learning with many primary care professionals at the RSM, which is a perfect setting to learn from each other and to network between professions. I will encourage outside bodies in health to make the most of these opportunities and promote the events to their members.” said Hutchinson.


5 Reasons why you should be tempted to attend Ophthalmic Drugs 2017 Event.

September 2017

SMi Group is proud to present Ophthalmic Drugs, gathering voices from some of the most senior industry thought leaders in ophthalmology such as Santen Inc, Aerie Pharmaceuticals, Novaliq, Bayer, Boehringer Ingelheim, Shire and Envisia Therapeutics.

Being held in London this November, Day 1 will explore novel approaches to treatment, ocular medical devices, targeted drug delivery technology, while Day 2 covers topics on therapies for diabetic macular oedema and real-life challenges to pre-clinical and clinical trials, to deepen your understanding of inherited ocular diseases.

1. Meet your future connections face-to-face - Not only will Ophthalmic Drugs highlight the newest surgical techniques and provide exposure to the latest technology and products, it will also put you face to face with influential people who can help you build a solid foundation in several key areas including, new ocular drugs, therapies for glaucoma, clinical results from long /short term studies and more!

2. Learn from the experts - Europe's leading ophthalmic event is a wonderful opportunity to learn about the latest and greatest in ophthalmology from the industry professionals themselves. Hear from Shire, Bayer, Novaliq, NightstaRx, Experimentica, Aerie Pharmaceuticals, Boehringer Ingelheim and more!

3. New Innovation - Shire's approach to meet unmet ophthalmic needs has been successful by developing lifitegrast, after being evaluated in four clinical trials. They have plans filing lifitegrast in multiple global markets by the end of 2017.

4. Benefit from interactive formats - Examine real-life case studies exploring clinical results from four 12-week efficacy and safety studies, and one long term (1-year) safety study and discovering unique properties to preservative free drugs.

5. Be social - Get yourself involved in discussions on social media by uploading pictures, video's and your views, using our hashtag on Twitter and LinkedIn: #ophdrugs

28th - 29th Nov 2017 | Kensington, London UK

Register here

Integumen signs Worldwide Patent Licence Agreement for remaining 50% of rights to Botox Booster IP

September 2017

Integumen (LSE: SKIN), the personal health care company developing and commercialising technology and products for the human integumentary system, is pleased to announce it has signed a worldwide Patent Licence Agreement with Dr Gary Hack for his co-rights to various patents and know-how related to enhancing and extending the cosmetic benefits of botulinum toxin (commonly known as Botox) treatments as well as dermal fillers and rosacea known as the “Botox Booster IP”.

• Botox Booster IP is an innovative and valuable new addition to our patent portfolio and complementary to the Visible Youth Professional product line. Visible Youth is a range of consumer and professional cosmeceutical products;

• The patents of Botox Booster IP include the use of Hyaluronic acid and bioactive glass powders to enhance and extend the beneficial cosmetic effects of certain non-surgical dermal interventions;

• The global market for facial aesthetics is forecast to reach $4.7 billion in 2018, of which the US is expected to contribute over US$2 billion;

• Visible Youth consumer range to be launched in 2018. Under the Agreement Integumen is due to pay an initial non-refundable consideration of $7,500 on or prior to October 31 2017 and will be liable to make additional milestone payments of up to $17,500 based on the issuance of patents in the US and Europe and the first sale or licensing of a product based on the Botox Booster IP.

In addition, Dr Hack will receive royalty payments of 0.75% of the net sales of licensed products marketed directly by integumen or 5% of all monies received by Integumen from the sub-licensing of the IP, including any upfront payments, milestones and royalties.

The Botox Booster IP was jointly developed by Dr. Asculai, the Chief Scientific Officer of Enhance Skin Product Inc. (“Enhance”) and Dr. Gary Hack. In March 2015 Enhance and Dr Hack filed an international application under the Patent Cooperation Treaty for the use of Hyaluronic acid and bioactive glass powder to enhance and extend the beneficial cosmetic effects of certain non-surgical dermal interventions, in particular the anti-wrinkle effects of cosmetic treatments associated with aesthetic injectables such as Botox®* (botulinum toxin) and cosmetic dermal fillers.

Additional applications may include the alleviation of symptoms of rosacea such as redness, dryness and itchiness. In late 2016 National applications were filed in the USA, European Union, Australia, New Zealand and China, regions where Integumen’s base patents are already granted. In December 2016 Integumen acquired all the IP and assets of Enhance.

Dr Hack is a Dental School Associate Professor in the Department of Advanced Oral Sciences and Therapeutics at the University of Maryland, School of Dentistry and the Director of Clinical Simulation.

Dr. Hack has worked in the field of dentistry for the past 40 years and has worked extensively for the past 25 years with bioactive glass powders. He currently has over 30 patents and patent applications related to the usage of bioactive glasses dating back to the 1990’s.

He is a co-inventor of NovaMin®**, a marketed dental product which involves the use of bioactive glass for the remineralisation and desensitisation of human tooth structure. He has collaborated with

Dr Asculai for a number of years on the application of bioactive glasses in the field of skincare which lead to this present invention.

Visible Youth™ Steeped in evidence-based science, Visible Youth Professional and Consumer skin care products contain the optimal size, purest and most effective HA molecular fraction and Bioactive Vitryxx®*** for deep penetrating hydration.

The unique line of proprietary formulations helps restore the skin’s natural supply of HA-water complex, resulting in long-lasting benefits for all skin types. The Company’s first six Visible Youth consumer products have recently completed formulation, stability and compatibility testing.

The first six products include; Multi-Peptide Super Serum, Multi Action Eye Serum, Moisture Shield SPF 20, Intensive Night Recovery, Skin Clarifying Essence and Replenishing Cleaning Melt. Three of the products have also undergone tests with a panel of 65 consumers with pleasing/ exciting results.

Heidelberg 9th Picture Competition in Vision Research & Ophthalmology ends September 30th.

August 2017

Heidelberg Picture competition

Send them your best photo to illustrate the fascination of clinical and basic research in ophthalmology and win attractive prizes.

The topic of the competition is "The Best Photo in Vision Research and Ophthalmology".

The photography may therefore illustrate all topics in the field of Ophthalmology & Vision Research. Be creative!

"The Best Photo in Vision Research and Ophthalmology" will receive:

1st Prize: 750,00 Euro
2nd Prize: 500,00 Euro
3rd Prize: 250,00 Euro

Competition Rules
In taking part in the Picture Competition 2017, you agree to the competiton rules.Please note: Individual participants can send up to a maximum of 3 pictures.Heidelberg Engineering is a high tech medical device company which designs, manufactures, and distributes diagnostic instruments for eye care professionals. The company’s products are used around the world by ophthalmologists and optometrists to scan patients’ eyes for signs of disease and to assist in the management of patients found to have disease. Early recognition of disease helps to delay and prevent the most common causes of blindness.

Full Competition Rules available here

How to send up to 3 images per entrant click here for online form


Eye health sector joined up to help patients remain independent.

August 2017

The Clinical Council for Eye Health Commissioning (CCEHC), which represents the major clinical professions and charity organisations in the eye-care sector, has launched a new Low vision, habilitation and rehabilitation framework for adults and children. The Framework – mainly aimed at commissioners and providers in health and social care – calls for more joined-up commissioning to ensure better access and consistency of services for users supported by the provision of appropriate equipment and expertise to improve quality of life.

Like the Primary Eye Care Framework, published on 2016, and the Community Ophthalmology Framework, published in 2015, the emphasis is on promoting integration across primary and community care, hospital eye service, education, social care, and charity and voluntary services to deliver better outcomes and eliminate duplication and waste of resources.

Low vision has a significant impact on a person’s independence and quality of life but low vision, habilitation and rehabilitation services for adults and children are not consistently available across England. In some areas, these services do not exist.

This has led to a new cross-sector initiative to ensure quality, reducing service variation, improving equity of access and enhancing outcomes through timely intervention.

Launching the new framework Parul Desai, Chair of the Clinical Council said; “Vision rehabilitation is crucial to ensuring that someone who loses their sight remains as independent as possible. A Department of Health funded research project has identified that good vision rehabilitation avoids significant health and social care costs; the costs avoided are more than three times the cost of delivering the service. Low vision is an essential part of the eye care and sight loss services and should be made available consistently across the country.”

The Clinical Council for Eye Health Commissioning (CCEHC) coordinates leading organisations from across eye health to offer united, evidence-based clinical advice and guidance to those commissioning and delivering eye health services in England on issues where national leadership is needed.

Its member organisations are:

• The Royal College of Ophthalmologists
• The College of Optometrists
• Association of Directors of Adult Social Services
• Association of British Dispensing Opticians
• British and Irish Orthoptic Society
• Faculty of Public Health
• Optical Confederation (including the Local Optical Committee Support Unit)
• Royal College of General Practitioners
• Royal College of Nursing (Ophthalmic nursing forum)
• Royal National Institute of Blind People
• International Glaucoma Association
• Macular Society
• VISION 2020 UK


Ophthalmic Drugs Conference: Advancing Your Ocular Drug Pipeline

August 2017

SMi Group are delighted to welcome your insights and have you join the discussions at Ophthalmic Drugs 2017.

Ophthalmic Drugs ConferenceHave your say and questions answered during our two pivotal sessions, presented by Oxford BioMedica and NightstaRx.

SMi Group are thrilled to present the launch of Ophthalmic Drugs conference taking place on 28th & 29th November in London, UK.

Ocular disease therapy has seen a surge in innovation in areas ranging from glaucoma to macular degeneration and diabetic retinopathy. As ageing populations grow globally the need for treatment in this field has grown and is expected to reach a figure of $21 billion by the year 2022* (Source: Business Wire: *

Ophthalmic Drugs will gather industry leaders to discuss the latest challenges and changes in the field of ophthalmology. Explore novel approaches to treatment, ocular medical devices, targeted drug delivery technology and real life challenges to pre-clinical and clinical trials in order to deepen your understanding of inherited ocular diseases.

Join us this November 2017 to arm yourself with the key requirements and tools for successful market entry through strategic direction on commercialisation; insight into potential therapeutic areas and critical updates on regulatory guidelines and stem cell therapy.

Do you have questions on novel endpoints in clinical trials? Looking to explore long-term clinical gene expression in patients? Interested in receiving progressive insight into the future of chronic ocular diseases?

DAY 1: Development of a Lentiviral Vector Platform for the Treatment of Chronic Ocular Disease
Speaker: Scott Ellis, Head of Early Development, Oxford BioMedica.

This presentation will introduce the LentiVector® platform for gene and cell therapy, enable you to experience translating from preclinical studies to First-in-Man clinical trials and explore current challenges and future goals.

DAY 1: Novel Endpoints in Ophthalmic Clinical Trials
Speaker: Aniz Girach, Chief Medical Officer, NightstaRx.

Get stuck in with NightstaRx as they examine how you can measure each key endpoint in a certain timescale, explore the pros and cons of these and gain a deeper understanding through the feedback of regulators on these endpoints.

Read full agenda here

Register by August 31st to save £300 online.

FDA Approves iDesign Advanced WaveScan Studio System to Treat Hyperopia With and Without Astigmatism.

July 2017

The FDA has approved a new indication for the Star S4 IR Excimer Laser System and iDesign System.

With the approval, the iDesign can be used for LASIK patients with hyperopia, with and without astigmatism.

In addition to myopia and mixed astigmatism, physicians can now treat hyperopia over a wide range of pupil sizes in patients who are 18 years and older. Capturing five different measurements in a single capture sequence – wavefront aberrometry, wavefront refraction, corneal topography, keratometry, and pupillometry – the iDesign System can help save time during the procedure.

"With its five-measurement capture sequence and high-definition sensor, the iDesign System creates an individualized treatment plan for each patient," Jay Pepose, MD, said in a Johnson & Johnson Vision news release.

"It’s now capable of treatment for a wider spectrum of patients who may have myopia, mixed astigmatism, or hyperopia. This broad range of treatment in one system will now offer more solutions to more patients."

Dr. Pepose served as a medical investigator for the clinical trial.

The new indication is for wavefront-guided LASIK for use in patients:

With hyperopia with and without astigmatism as measured by the iDesign System up to +4.00 D spherical equivalent, with up to 2.00 D cylinder;

With agreement between manifest refraction (adjusted for optical infinity) and the iDesign System refraction as follows:

Spherical Equivalent: Magnitude of the difference is less than 0.625 D;
Cylinder: Magnitude of the difference is less than or equal to 0.5 D;
18 years of age or olderWith refractive stability (a change of <.1.0 D in sphere or cylinder for a minimum of 12 months prior to surgery)

Bausch + Lomb Launches Fortifeye Capsular Tension Ring.

July 2017

Bausch + Lomb announced the US launch of the FortifEYE capsular tension ring (CTR), a preloaded, sterile, nonoptical implant indicated for the stabilization of the crystalline lens capsule in the presence of weak or partially absent zonules in adult patients undergoing cataract extraction with intraocular lens implantation.

Conditions associated with weak or partially absent zonules may include primary zonular weakness (e.g., Marfan syndrome), secondary zonular weakness (e.g., trauma or vitrectomy), cases of zonulysis, cases of pseudoexfoliation, and cases of Weill-Marchesani syndrome.

“Capsular tension rings can play an important role in complex cataract cases, and they must be both effective and easy to use during these procedures,” Chuck Hess, vice president and general manager, U.S. Surgical, Bausch + Lomb, said in a company news release. “The FortifEYE CTR with preloaded single-use injector simplifies insertion allowing for safe, immediate preparation and use.”

The FortifEYE CTRs are sterile, nonoptical implants made up of one continuous piece of polymethyl methacrylate (PMMA), available in both clockwise (right-handed) and counterclockwise (left-handed) insertion options, and are available in a variety of diameters, including 10mm, 11mm, and 12mm (compressed).

CTRs have been shown to preserve the integrity of the capsular bag diameter, capsulorhexis size, and IOL shape, allowing for good anatomical IOL centration. CTRs also have been shown to be a safe and effective ancillary method to delay the incidence, onset, and magnitude of posterior capsular opacification and reduce postsurgical decentration and tilt to allow for excellent optical performance of multifocal and plate-haptic IOLs.

(news from Eyewiretoday)

Review of artificial vision technologies showing that the Argus II bionic eye is fundable.

July 2017

Currently under funding review by NHS England, this recently published review show that the technology provides sufficient cost savings and patient benefits to justify its funding by the NHS.

The review has been published by the RCO in their Eye Journal.

PE StangaThe pursuit is now on to improve artificial visual function. Two retinal implants appear the most likely to succeed in the future having undergone multicentre human trials: the Argus II electronic epiretinal device (Second Sight Medical Products, CA, USA) and Alpha-IMS electronic subretinal device (Retina Implant AG, Germany).

The trial results to date are encouraging with visual improvement and acceptable safety profiles reported for both devices.

At present, the visual function generated by either device does not offer high enough resolution or acuity for a patient to regain a fully functional life. Despite this, both devices not only have the potential, but have actually improved the vision-related quality of life in a significant number of patients implanted. With this in mind, the economic argument is clear. Provided device-life is long enough, its cost should be acceptable for the obtained improvement in the quality of life.

The aim of this Review Article is to assist those readers that may be considering offering any of these devices as a treatment for blindness in Retinitis Pigmentosa. Download and read the full Review Document here.


Office Giant
Primary Health Net